Reilly, Joseph
Jacobs, Micah A.
Friedman, Bruce
Cleveland, Kerry O.
Lombardi, David A.
Castaneda-Ruiz, Bibiana
Clinical trials referenced in this document:
Documents that mention this clinical trial
Clinical Experience with Telavancin for the Treatment of Patients with Bacteremia and Endocarditis: Real-World Results from the Telavancin Observational Use Registry (TOUR™)
https://doi.org/10.1007/s40801-020-00191-x
Real-World Clinical Use and Outcomes of Telavancin for the Treatment of Bone and Joint Infections: Results from the Telavancin Observational Use Registry (TOUR™)
https://doi.org/10.1007/s40801-021-00255-6
Funding for this research was provided by:
Theravance Biopharma US
Article History
First Online: 5 May 2020
Compliance with Ethical Standards
:
: JR has served on advisory boards and speakers bureaus for Theravance Biopharma and Cumberland Pharmaceuticals Inc. MAJ has received payment for participating in speakers’ bureaus, advisory boards for Theravance Biopharma, Cumberland Pharmaceuticals Inc, and Allergan; payment for serving on speakers’ bureau for Merck & Co. (including former Cubist Pharmaceuticals); and received research support from Theravance Biopharma related to TOUR and from Allergan. BF has received payment for participating in speakers’ bureaus for Theravance Biopharma, Allergan, Melinta, Merck & Co., and La Jolla Pharmaceutical. KC has received payment for participating in speakers’ bureaus for Allergan, Merck & Co., Theravance Biopharma, and Cumberland Pharmaceuticals Inc; consulting fees for Theravance Biopharma; and grants from Theravance Biopharma for the collection of data were paid to Methodist Healthcare of Memphis. DL is an employee of Theravance Biopharma US, Inc. BC-R was an employee of Theravance Biopharma US, Inc. during the conduct of the study and owns stock in Theravance Biopharma, Inc.
: The Copernicus Group Independent Review Board approved the TOUR observational study protocol on 29 December 2015. This was an observational use study with data collected via retrospective medical chart review, therefore signed informed consent from the patient was not required. Only de-identified information was collected in accordance with section 164.514 of the Health Insurance Portability and Accountability Act Privacy Rule.